1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR

CXCR

CXC chemokine receptors; C-X-C motif chemokine receptors

CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10971
    Nef-M1
    Antagonist
    Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer.
    Nef-M1
  • HY-103010
    MSX-130
    Antagonist 98.00%
    MSX-130 is a CXCR4 antagonist. MSX-130 inhibits cancer metastasis.
    MSX-130
  • HY-RS03406
    CXCR4 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR4 Human Pre-designed siRNA Set A
  • HY-P1104
    FC131
    Antagonist
    FC131 is a potent CXCR4 antagonist. FC131 inhibits [125I]-SDF-1 binding to CXCR4 with an IC50 of 4.5 nM. FC131 has anti-HIV activity.
    FC131
  • HY-P991781
    Anti-Mouse CXCR6 Antibody (Cx6Mab-1)
    Inhibitor
    Anti-Mouse CXCR6 Antibody (Cx6Mab-1) reacts with the N-terminal extracellular ligand-binding domain of mouse CXCR6. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).
    Anti-Mouse CXCR6 Antibody (Cx6Mab-1)
  • HY-RS03407
    Cxcr4 Mouse Pre-designed siRNA Set A
    Inhibitor

    Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr4 Mouse Pre-designed siRNA Set A
  • HY-10011B
    (Rac)-SCH 563705
    Antagonist 99.78%
    (Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC50 values ​​of 1.3 nM and 7.3 nM and Ki values ​​of 1 nM and 3 nM, respectively.
    (Rac)-SCH 563705
  • HY-P992014
    Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)
    Inhibitor
    Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3.
    Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)
  • HY-P990390
    Anti-CXCL12/SDF1a Antibody
    ≥99.0%
    Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCL12/SDF1a Antibody
  • HY-160041B
    Olaptesed pegol sodium scrambled negative control
    Inhibitor
    Olaptesed pegol sodium scrambled negative control is the sequence scrambled negative control of Olaptesed pegol sodium.
    Olaptesed pegol sodium scrambled negative control
  • HY-144347
    HF51116
    Antagonist
    HF51116 is a potent antagonist of CXCR4. HF51116 strongly antagonizes SDF-1α-induced cell migration, calcium mobilization, and CXCR4 internalization. HF51116 inhibits HIV-1 infection via CXCR4. HF51116 has the potential for the research of HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis.
    HF51116
  • HY-10046S
    Plerixafor-d4
    Antagonist
    Plerixafor-d4 is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM.
    Plerixafor-d<sub>4</sub>
  • HY-18263
    Elubrixin hydrochloride
    Antagonist
    Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin hydrochloride
  • HY-P990389
    Anti-CXC-ELR Antibody
    Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-CXC-ELR Antibody
  • HY-124056
    AZ10397767
    Antagonist
    AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC50 of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo.
    AZ10397767
  • HY-179387
    CXCR2-IN-3
    Inhibitor
    CXCR2-IN-3 is a CXCR2 inhibitor with an IC50 of 11.37 μM. CXCR2-IN-3 mediates CXCR2-Ca2+ signalling inhibition halted autophagic flux, subsequently facilitating ROS-mediated apoptotic cell death. CXCR2-IN-3 suppresses the CXCR2-NLRP3 canonical pathway, suppressing pre-tumorigenic markers. CXCR2-IN-3 causes autophagy-dependent cell death in polyploid giant cancer cells (PGCCs). CXCR2-IN-3 can be used for the research of oral squamous cell carcinoma (OSCC).
    CXCR2-IN-3
  • HY-RS03401
    Cxcr2 Mouse Pre-designed siRNA Set A
    Inhibitor

    Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr2 Mouse Pre-designed siRNA Set A
  • HY-155698
    Mz438
    Mz438 is high-affinity and selective fluorescent CXCR2 ligand. Mz438 is a small-molecule-based fluorescent probe targeting the IABS of CXCR2.
    Mz438
  • HY-N2573A
    Corydalmine hydrochloride
    Inhibitor
    Corydalmine hydrochloride inhibits spore germination of some plant pathogenic as well as saprophytic fungi. Corydalmine hydrochloride acts as an oral analgesic agent, exhibiting potent analgesic activity. Corydalmine hydrochloride alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway.
    Corydalmine hydrochloride
  • HY-P991656
    LY-2624587
    Antagonist
    LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research.
    LY-2624587
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.